• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童垂体腺瘤:临床表现、生化特征及长期预后。

Paediatric Pituitary Adenomas: Clinical Presentation, Biochemical Profile and Long-Term Prognosis.

机构信息

Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Department of Translational and Regenerative Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

出版信息

Neurol India. 2022 Jan-Feb;70(1):304-311. doi: 10.4103/0028-3886.338667.

DOI:10.4103/0028-3886.338667
PMID:35263901
Abstract

CONTEXT

Paediatric pituitary adenomas (PPAs) are uncommon, with evidence confined to small cohorts.

AIM

We aimed to elucidate the baseline profile and outcomes of PPAs in a large, contemporary, monocentric cohort.

SETTINGS, DESIGN: Pituitary clinic at PGIMER over 8 years (2010-2018).

SUBJECTS AND METHODS

PPAs in patients (≤20 years at diagnosis) were included. A retrospective review of their baseline clinico-biochemical and radiological profiles and outcomes post pituitary surgery/medical management was performed.

RESULTS

There were a total of 74 patients, of which 42 were female. The median age was 15 (IQR 13-18) years. Corticotropinomas (32.4%) and somatotropinomas (25.7%) were common, with 1 case of TSHoma and pituitary blastoma. The most common presentation was headache (57%) overall and menstrual irregularities (64.2%) in girls. Most (78%) had macroadenomas. Prolactinomas showed an excellent response to primary medical therapy (83.3%). Transsphenoidal surgery was performed in 81% of patients. Diabetes insipidus (30%) and hyponatremia (26.7%) emerged as common postoperative complications. Adjuvant medical management was required in 25%, and radiotherapy in 18%. Remission rates in Cushing's and acromegaly were 62.5% and 57.8%, respectively, with long-term hormone deficits noted in one-third of patients.

CONCLUSION

PPAs have unique features and management challenges, including effects on growth and puberty. Functional tumours and macroadenomas are common. Remission can be achieved in more than half of the patients, with endocrine deficits persisting in about a third of cases, needing long-term surveillance.

摘要

背景

儿科垂体腺瘤(PPAs)较为少见,目前的证据仅限于小队列研究。

目的

我们旨在阐明大型单中心队列中 PPAs 的基线特征和结局。

地点、设计:PGIMER 垂体科 8 年(2010-2018 年)的病例。

研究对象和方法

纳入了患者(诊断时≤20 岁)的 PPAs。对他们的基线临床-生物化学和影像学特征以及接受垂体手术后/药物治疗后的结局进行回顾性分析。

结果

共纳入 74 例患者,其中 42 例为女性。中位年龄为 15(IQR 13-18)岁。促肾上腺皮质激素瘤(32.4%)和生长激素瘤(25.7%)较常见,有 1 例 TSH 瘤和垂体胚细胞瘤。最常见的表现是头痛(总体 57%)和女孩的月经不规律(64.2%)。大多数(78%)为大腺瘤。催乳素瘤对原发性药物治疗有良好的反应(83.3%)。81%的患者接受了经蝶窦手术。术后常见的并发症有尿崩症(30%)和低钠血症(26.7%)。25%的患者需要辅助药物治疗,18%的患者需要放射治疗。库欣病和肢端肥大症的缓解率分别为 62.5%和 57.8%,三分之一的患者出现长期激素缺乏。

结论

PPAs 具有独特的特征和管理挑战,包括对生长和青春期的影响。功能性肿瘤和大腺瘤较常见。超过一半的患者可以实现缓解,三分之一的患者持续存在内分泌缺陷,需要长期监测。

相似文献

1
Paediatric Pituitary Adenomas: Clinical Presentation, Biochemical Profile and Long-Term Prognosis.儿童垂体腺瘤:临床表现、生化特征及长期预后。
Neurol India. 2022 Jan-Feb;70(1):304-311. doi: 10.4103/0028-3886.338667.
2
Factors influencing the outcome of microsurgical transsphenoidal surgery for pituitary adenomas: a study on 184 patients.影响经蝶窦显微手术治疗垂体腺瘤效果的因素:184 例患者研究。
Hormones (Athens). 2013 Apr-Jun;12(2):254-64. doi: 10.14310/horm.2002.1409.
3
Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.促甲状腺激素分泌型垂体腺瘤的临床病理特征及治疗结果:一项90例的单中心研究
J Neurosurg. 2014 Dec;121(6):1462-73. doi: 10.3171/2014.7.JNS1471. Epub 2014 Sep 19.
4
[Transsphenoidal resection of pituitary adenomas: long-term results from the Leiden University Medical Center].[经蝶窦垂体腺瘤切除术:来自莱顿大学医学中心的长期结果]
Ned Tijdschr Geneeskd. 2008 Nov 22;152(47):2565-70.
5
Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.对115例因肢端肥大症接受经蝶窦手术的患者进行长期内分泌随访评估。
J Neurosurg. 1998 Sep;89(3):353-8. doi: 10.3171/jns.1998.89.3.0353.
6
Double, synchronous pituitary adenomas causing acromegaly and Cushing's disease. A case report and review of literature.双重、同步性垂体腺瘤导致肢端肥大症和库欣病。病例报告及文献复习。
Endocr Pathol. 2013 Jun;24(2):92-9. doi: 10.1007/s12022-013-9237-z.
7
Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.肢端肥大症患者经蝶窦手术后生长激素分泌性垂体腺瘤的预后因素。
World Neurosurg. 2021 Feb;146:e1360-e1366. doi: 10.1016/j.wneu.2020.12.013. Epub 2020 Dec 9.
8
Pituitary adenomas in older adults (≥ 65 years): 90-day outcomes and readmissions: a 10-year endoscopic endonasal surgical experience.老年(≥65 岁)垂体腺瘤:90 天结局和再入院:10 年内镜经鼻手术经验。
Pituitary. 2021 Feb;24(1):14-26. doi: 10.1007/s11102-020-01081-9. Epub 2020 Sep 16.
9
Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.单纯内镜经蝶窦手术治疗肢端肥大症:垂体中心治疗 67 例的结果。
Neurosurg Focus. 2010 Oct;29(4):E7. doi: 10.3171/2010.7.FOCUS10167.
10
Transsphenoidal surgery for pituitary adenomas in pediatric patients: a multicentric retrospective study.儿童垂体腺瘤的经蝶窦手术:一项多中心回顾性研究。
Childs Nerv Syst. 2019 Nov;35(11):2119-2126. doi: 10.1007/s00381-019-04179-z. Epub 2019 May 11.

引用本文的文献

1
Clinical, hormonal and radiological features, and treatment outcomes of prolactinomas in a pediatric population.儿科人群中泌乳素瘤的临床、激素和放射学特征及治疗结果
North Clin Istanb. 2024 Mar 29;12(3):269-276. doi: 10.14744/nci.2024.65049. eCollection 2025.
2
Giant Prolactin-Secreting Pituitary Adenoma: A Case Report and Literature Review.巨大泌乳素分泌型垂体腺瘤:一例报告及文献复习
Cureus. 2025 May 31;17(5):e85126. doi: 10.7759/cureus.85126. eCollection 2025 May.
3
Pediatric Pituitary Adenomas and Cysts: A 46-Year Population-Based Analysis.
小儿垂体腺瘤和囊肿:一项基于人群的46年分析
J Endocr Soc. 2025 Apr 24;9(6):bvaf069. doi: 10.1210/jendso/bvaf069. eCollection 2025 Jun.
4
Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations.儿童和青少年垂体腺瘤诊断和管理的共识指南:第 1 部分,一般建议。
Nat Rev Endocrinol. 2024 May;20(5):278-289. doi: 10.1038/s41574-023-00948-8. Epub 2024 Feb 9.
5
Pituitary macroadenomas in childhood and adolescence: a clinical analysis of 7 patients.儿童及青少年垂体大腺瘤:7例临床分析
Clin Diabetes Endocrinol. 2023 Oct 31;9(1):5. doi: 10.1186/s40842-023-00153-6.
6
Clinical and therapeutic outcomes of pediatric pituitary adenomas: a single pituitary center experience.小儿垂体腺瘤的临床治疗效果:单中心经验
Endocrine. 2024 Jan;83(1):160-170. doi: 10.1007/s12020-023-03523-3. Epub 2023 Oct 2.
7
Neuroimaging of pediatric tumors of the sellar region-A review in light of the 2021 WHO classification of tumors of the central nervous system.蝶鞍区小儿肿瘤的神经影像学——基于2021年世界卫生组织中枢神经系统肿瘤分类的综述
Front Pediatr. 2023 Jun 21;11:1162654. doi: 10.3389/fped.2023.1162654. eCollection 2023.
8
Gigantism: microsurgical treatment by transsphenoidal approach and prognostic factors.巨人症:经蝶窦入路的显微外科治疗及预后因素。
Pituitary. 2023 Feb;26(1):51-56. doi: 10.1007/s11102-022-01286-0. Epub 2022 Nov 6.